Burke JM et al. Efficacy and safety of umbralisib, ublituximab (U2), and U2 plus bendamustine in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). ASH 2021;Abstract 527.
Eichhorst B et al. A randomized phase III study of venetoclax-based time-limited combination treatments (RVe, GVe, GIVe) vs standard chemoimmunotherapy (CIT: FCR/BR) in frontline chronic lymphocytic leukemia (CLL) of fit patients: First co-primary endpoint analysis of the international intergroup GAIA (CLL13) trial. ASH 2021;Abstract 71.
Ghia P et al. Ibrutinib treatment in the first-line setting for patients with chronic lymphocytic leukemia: Up to 7 years of follow-up in the resonate-2 study. EHA 2021;Abstract EP636.
Hillmen P et al. First interim analysis of ALPINE study: Results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. EHA 2021;Abstract LB1900.
Hillmen P et al. First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia. EHA 2021;Abstract S145.
Hillmen P et al. Ibrutinib plus rituximab is superior to FCR in previously untreated CLL: Results of the phase III NCRI FLAIR trial. ASH 2021;Abstract 642.
Mato AR et al. Pirtobrutinib, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL/SLL: Updated results from the phase 1/2 BRUIN study. ASH 2021;Abstract 391.
Munir T et al. First prospective data on minimal residual disease (MRD) outcomes after fixed-duration ibrutinib plus venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of CLL in elderly or unfit patients: The GLOW study. ASH 2021;Abstract 70.
Sharman J et al. Acalabrutinib ± obinutuzumab vs obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: ELEVATE-TN 4-year follow-up. EHA 2021;Abstract S148.
Tam CS et al. SEQUOIA: Results of a Phase 3 randomized study of zanubrutinib versus bendamustine + rituximab (BR) in patients with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). ASH 2021;Abstract 396.
Woyach JA et al. Long-term results of alliance A041202 show continued advantage of ibrutinib-based regimens compared with bendamustine plus rituximab (BR) chemoimmunotherapy. ASH 2021;Abstract 639.